Why MannKind Stock Tumbled on Thursday
(NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest earnings release to be lacking -- despite a significant top-line beat. MannKind closed the day down more than 7% in value.
MannKind released its fourth-quarter and full-year 2025 results before market open, reporting that revenue grew 46% year over year to just under $112 million. However, that period's tally includes almost $22.9 million from sales of edema treatment Furoscix. This became part of the company's portfolio following the October 2025 acquisition of the drug's developer, scPharmaceuticals.
Image source: Getty Images.
Source Fool.com
MannKind Corp. Aktie
2,09 €
1,02 %
Und MannKind Corp. steht derzeit mit 25 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung bei unserer Community hoch im Kurs.
Das von der Community festgelegte Kursziel für MannKind Corp. von 7 € würde den aktuellen Kurs von 2.09 € mehr als verdoppeln.
